3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
2
Endocrine
1
Dermatologic
1
Breast
1
Conditions
Breast Neoplasms
15
Inflammatory Breast Neoplasms
3
Breast Neoplasms, Male
3
Recurrence
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lymphoma, Non-Hodgkin
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large-Cell, Immunoblastic
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma, B-Cell, Marginal Zone
2
Lymphoma
2
Leukemia, Myeloid, Acute
2
Leukemia, Lymphocytic, Chronic, B-Cell
2
Leukemia
2
Hodgkin Disease
2
Burkitt Lymphoma
2
Waldenstrom Macroglobulinemia
1
Testicular Neoplasms
1
Testicular Germ Cell Tumor
1
Sarcoma
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pancreatic Neoplasms
1
Neuroectodermal Tumors, Primitive, Peripheral
1
Neuroblastoma
1
Neoplasms, Plasma Cell
1
Neoplasms
1
Muscle Neoplasms
1
Interventions
pembrolizumab
29
Gemcitabine
16
Cyclophosphamide
14
Nivolumab
12
Carboplatin
12
Capecitabine
11
Trastuzumab
9
Paclitaxel
9
Magnetic Resonance Spectroscopy
8
Irinotecan
8
Bevacizumab
8
Albumin-Bound Paclitaxel
8
130-nm albumin-bound paclitaxel
8
olaparib
7
fludarabine
7
Docetaxel
7
spartalizumab
6
aldesleukin
6
Drug Therapy
6
Cisplatin
6
durvalumab
5
atezolizumab
5
Standard of Care
5
Specimen Handling
5
Oxaliplatin
5
Biopsy
5
sargramostim
4
palbociclib
4
niraparib
4
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Pancreatic Neoplasms
×
Melphalan
×
Breast
×
Clear all
NCT04150042
2026-01-29
SHARON
General Oncology, Inc.
Phase 1
Recruiting
24 enrolled